Gemphire Therapeutics Inc. has amended the license agreement with Pfizer covering gemcabene. Gemphire licensed exclusive worldwide commercial rights to gemcabene from Pfizer in 2011. Under the original agreement, Pfizer had the right to terminate the license if the drug was not adequately commercialized by April 2021. The amended and restated agreement extends the deadline for the first commercial sale to April 2024. The royalty period in countries in which gemcabene becomes approved for comm...